Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3356 |
|
| Actual shortage: | 218 (6%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 10 (0%) | |
| Resolved: | 3128 (93%) | |
Discontinuation Reports |
359 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 335 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
61 (25%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-CARVEDILOL | 12.5MG | TABLET | Resolved | 2017-11-28 | 2018-05-27 | 30992 |
| APO-CARVEDILOL | 12.5MG | TABLET | Resolved | 2023-09-01 | 2023-11-17 | 203554 |
| APO-CEFACLOR | 250MG | CAPSULE | Actual shortage | 2017-08-13 | 2017-10-05 | 19036 |
| APO-CEFACLOR | 500MG | CAPSULE | Actual shortage | 2017-08-13 | 2017-10-05 | 19039 |
| APO-CEFACLOR | 125MG | POWDER | Actual shortage | 2017-08-13 | 2017-10-05 | 19066 |
| APO-CEFACLOR | 250MG | POWDER | Actual shortage | 2017-08-13 | 2017-10-05 | 19069 |
| APO-CEFACLOR | 375MG | POWDER | Actual shortage | 2017-08-13 | 2017-10-05 | 19072 |
| APO-CEFADROXIL | 500MG | CAPSULE | Resolved | 2024-07-25 | 2024-08-09 | 233706 |
| APO-CEFADROXIL | 500MG | CAPSULE | Resolved | 2024-09-12 | 2024-10-11 | 237372 |
| APO-CEFADROXIL | 500MG | CAPSULE | Resolved | 2024-11-14 | 2024-12-13 | 243086 |
| APO-CEFADROXIL | 500MG | CAPSULE | Resolved | 2019-07-12 | 2019-11-25 | 89155 |
| APO-CEFADROXIL | 500MG | CAPSULE | Resolved | 2023-04-21 | 2024-03-08 | 190008 |
| APO-CEFADROXIL | 500MG | CAPSULE | Resolved | 2025-01-16 | 2025-02-28 | 247862 |
| APO-CEFADROXIL | 500MG | CAPSULE | Resolved | 2021-07-23 | 2021-10-12 | 142973 |
| APO-CEFADROXIL | 500MG | CAPSULE | Resolved | 2017-04-17 | 2017-04-25 | 7102 |
| APO-CEFADROXIL | 500MG | CAPSULE | Resolved | 2022-11-20 | 2022-12-23 | 175327 |
| APO-CEFEPIME | 1G | POWDER FOR SOLUTION | Resolved | 2022-04-08 | 2022-08-24 | 158348 |
| APO-CEFEPIME | 1G | POWDER FOR SOLUTION | Resolved | 2019-03-27 | 2019-03-29 | 79574 |
| APO-CEFEPIME | 2G | POWDER FOR SOLUTION | Resolved | 2019-07-31 | 2019-08-02 | 90341 |
| APO-CEFEPIME | 2G | POWDER FOR SOLUTION | Resolved | 2019-12-05 | 2020-02-18 | 100265 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |